share_log

信达生物将在美国糖尿病协会大会(ADA 2024)报告玛仕度肽的多项临床研究数据

Innovent bio will report multiple clinical trial data of Marzidoc peptide at the American Diabetes Association Conference (ADA 2024).

PR Newswire ·  Jun 12 08:00

On June 12, 2024, San Francisco, USA, and Suzhou, China / PRNewswire / - Innovent Biologics, Inc. (stock code: 01801.HK), a biopharmaceutical company dedicated to the research and development, production, and sales of innovative drugs in the fields of tumors, self-immunity, metabolism, cardiovascular, ophthalmology and other major diseases, announced that multiple clinical research data of Mazdutide will be reported in the form of late-breaking oral presentations and posters at the 84th Scientific Sessions of the American Diabetes Association (ADA), including Mazdutide's first weight loss, the GLORY-1 Phase III registration clinical study, a liver fat content exploratory study, and Mazdutide's second weight loss, the GLORY-1 Phase II clinical study. The conference will be held in Orlando, USA from June 21-24, 2024. Details are as follows:The first weight lossIIIRegistration Clinical StudyGLORY-1,GLORY-1Liver Fat Content Exploratory Study, and9mgWeight lossIIClinical Study.The conference will be held on June 21-24, 2024, in Orlando, USA..Details are as follows:

Title:Efficacy and Safety of Mazdutide in Chinese Participants with Overweight or Obesity (GLORY-1)

Abstract Number: 1856-LB
Presentation Form: Oral Presentation (ePoster Theater)
Time: June 23, 2024, 13:30 PM - 13:40 PM (US Eastern Time)
Speaker: Professor Ji Linong, Peking University People's Hospital

Title:Improvement of liver steatosis by Mazdutide in Chinese participants with overweight or obesity - An exploratory analysis of GLORY-1.

Abstract number: 1857-LB.
Presentation format: Poster presentation.

Title:A Phase 2 Study of Mazdutide 9 mg in Chinese Adults with BMI of 30 kg/m or more.2Or more.

Abstract number: 1866-LB.
Presentation format: Poster presentation.

Innovent Bio.Dr. Qian Lei, Vice President of Clinical Development, said: 'Mazdutide is the world's first GLP-1R/GCGR dual agonist to complete a Phase III registration study and succeed in overweight/obese populations. We are thrilled to present the results of the first Phase III clinical study of Mazdutide, GLORY-1, at the ADA conference. In addition, the results of the Phase II study of Mazdutide 9 mg in Chinese patients with moderate to severe obesity are also exciting, and the corresponding Phase III study, GLORY-2, is currently underway. Mazdutide is the first weight loss drug to provide differentiated treatment options for obese individuals of different degrees, with the aim of providing more personalized, effective, and safe weight loss drug treatment options for overweight and obese populations.'"Mashidu peptide is the world's first GLP-1R / GCGR dual agonist that has completed Phase III registration studies in overweight/obese populations and achieved success. We are pleased to announce the results of the GLORY-1 Phase III clinical study of Mashidu peptide at the ADA conference. At the same time, the Phase II study results of Mashidu peptide 9 mg in Chinese moderately to severely obese patients was also exciting, and the corresponding Phase III study GLORY-2 is currently underway. Mashidu peptide is the first weight loss drug to provide differentiated treatment plans for obese people at different levels, aiming to provide more personalized, effective, and safe weight loss drug treatment plans for overweight and obese people."

About Mazdutide (IBI362)Mazdutide (IBI362) is a GLP-1R/GCGR dual agonist jointly developed by Innovent Bio and Eli Lilly and Co. As a natural gastric acid regulator similar to oxyntomodulin (OXM) in the human body, Mazdutide, in addition to promoting insulin secretion, reducing blood sugar and body weight by activating GLP-1R, can also increase energy consumption and enhance weight loss efficacy by activating GCGR, and improve liver fat metabolism. Mazdutide has demonstrated excellent weight-loss and blood sugar-lowering effects, as well as multiple metabolic benefits such as reduced waist circumference, blood lipids, blood pressure, uric acid, liver enzymes, and liver fat content, and improved insulin sensitivity in multiple clinical studies. At present, five Phase III clinical studies of Mazdutide in Chinese overweight or obese (GLORY-1 and GLORY-2) subjects and type 2 diabetes (DREAMS-1, DREAMS-2, and DREAMS-3) subjects are underway. Among them, the GLORY-1 and DREAMS-2 studies have achieved the main endpoints.)

Innovent Bio is committed to developing, manufacturing and selling innovative drugs in major disease areas such as oncology, metabolism and cardiovascular, autoimmune, and ophthalmology. The company has 10 approved products on the market, 4 products under NMPA review, 4 new drug molecules in Phase III or pivotal clinical studies, and 18 new drug varieties in clinical studies. The company has deep cooperation with domestic and foreign pharmaceutical companies to accelerate drug innovation, and has reached more than 30 strategic cooperation agreements with international partners such as Eli Lilly and Co., Roche, Sanofi, Adimab, Incyte, and MD Anderson Cancer Center.

In February 2024, the first NDA of Mazdutide was accepted by the NMPA for long-term weight control in adult obese or overweight patients.

"Starting with trust and ending with action", developing high-quality biopharmaceuticals that the general public can afford is the ideal and goal of Innovent Biologics. Innovent Biologics was established in 2011 and is committed to the development, production, and sales of innovative drugs to treat major diseases such as tumors, metabolic diseases, and autoimmune diseases. On October 31, 2018, Innovent Biologics went public on the Main Board of the Hong Kong Stock Exchange with stock code: 01801. Since its establishment, the company has stood out among many biopharmaceutical companies with its innovative achievements and international operating model. It has established a product chain including 23 new drug varieties, covering multiple disease areas such as tumors, metabolic diseases, and autoimmune diseases, of which 6 varieties have been selected for the national "Major New Drug Creation" special project, and 3 products (Sintilimab Injection, brand name: Tyvyt, English trademark: TYVYT; Bevacizumab Injection, brand name: Duligotong, English trademark: BYVASDA; Camrelizumab Injection, brand name: Sulinno, English trademark: SULINNO) have been approved.

'Starting in trust and delivering in action' and developing high-quality biopharmaceuticals that ordinary people can afford is the mission and goal of Innovent Bio. Innovent Bio was founded in 2011, and is committed to developing, manufacturing and selling innovative drugs in major disease areas such as oncology, metabolism and cardiovascular, autoimmune, and ophthalmology. The company has 10 approved products on the market, 4 products under NMPA review, 4 new drug molecules in Phase III or pivotal clinical studies, and 18 new drug varieties in clinical studies. The company has reached more than 30 strategic cooperation agreements with international partners such as Eli Lilly and Co., Roche, Sanofi, Adimab, Incyte, and MD Anderson Cancer Center. While continuously developing innovative drugs and seeking its own development, Innovent Bio always harbors a scientific and benevolent heart, adheres to the principle of 'patient-centered', cares for patients and their families, and actively fulfills its social responsibilities. Innovent Bio hopes to work together with everyone to improve the development level of China's biopharmaceutical industry, to meet the accessibility of people's medicine and the pursuit of good wishes for life and health.

Please visit the company's website, Biologics, for details.

Statement: Innovent Bio does not recommend unapproved drugs.

Innovent Bio does not recommend unapproved drugs./Use for indications.

Forward-looking statements

This press release may contain certain forward-looking statements. These statements inherently involve risks and uncertainties. When using words such as "expect," "believe," "anticipate," "intend," "plan," and other similar expressions, it is the company's intention to identify forward-looking statements. The company has no obligation to continually update these forward-looking statements.

These forward-looking statements are based on management's current views, assumptions, expectations, estimates, forecasts, and understandings of future events, which are inherently subject to risks, uncertainties, and other factors, some of which are beyond the company's control, and may be difficult to predict. Therefore, actual results may differ materially from those included in the forward-looking statements due to future changes and developments in our business, competitive environment, politics, economy, laws, and social circumstances.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment